Tecfidera (Dimethyl Fumarate)
Brand Names: Tecfidera
Methodology & AI Transparency ⓘ
Tecfidera (Dimethyl Fumarate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Tecfidera and registered by Biogen Inc., this multiple sclerosis agent product delivers active moiety Dimethyl Fumarate (cross-referenced at /meds/dimethyl-fumarate) (240 mg/1 Capsule; 120 mg/1 Capsule).
- 2 Real-world patient consensus: Tecfidera links directly to generic Dimethyl Fumarate (/meds/dimethyl-fumarate) under FDA SPL 2024-06-27 (NDC 64406-006).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $9.05 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Tecfidera (Dimethyl Fumarate): nausea (12.2%), diarrhea (9.5%), abdominal discomfort (5%).
Ask our AI Specialists anything about Tecfidera (Dimethyl Fumarate)
Tecfidera (Dimethyl Fumarate) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Tecfidera and registered by Biogen Inc., this multiple sclerosis agent product delivers active moiety Dimethyl Fumarate (cross-referenced at /meds/dimethyl-fumarate) (240 mg/1 Capsule; 120 mg/1 Capsule). Federal labeling (2024-06-27, RxCUI 1373483-B64406006) defines its therapeutic scope: Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS),.
Inside Tecfidera, Dimethyl Fumarate mediates multiple sclerosis agent pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (240 mg/1 Capsule; 120 mg/1 Capsule). Commercial labeling registered by Biogen Inc. (SPL 2024-06-27, RxNorm 1373483-B64406006) pairs standardized excipient stability with federal price transparency metrics ($0.9402/unit NADAC; $34.50 retail average).
Following administration (240 mg/1 Capsule), Tecfidera (Dimethyl Fumarate) achieves Systemic oral bioavailability of roughly 76%–88% following first-pass transit bioavailability and initial pharmacodynamic onset within 1–4 hrs (peak cmax) for tecfidera (dimethyl fumarate) onset, governed by a Biphasic clearance with 8–21 hr terminal t½ under Tecfidera (Dimethyl Fumarate) maintenance terminal half-life through hepatic enzymatic processing and renal clearance proportional to creatinine clearance (tecfidera (dimethyl fumarate)).
Before initiating Tecfidera (Dimethyl Fumarate) at 240 mg/1 Capsule, clinical safety checklists rule out known hypersensitivity to dimethyl fumarate or structurally related multiple sclerosis agent compounds; concomitant contra-labeled cyp/transporter therapies during active tecfidera (dimethyl fumarate) administration. Logged tolerability patterns center on nausea (12.2% of reports), diarrhea (9.5% of reports), headache (8.2% of reports).
Avoid overlapping multiple sclerosis agent prescriptions alongside Tecfidera (Dimethyl Fumarate) to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Tecfidera (Dimethyl Fumarate) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Dimethyl Fumarate or structurally related multiple sclerosis agent compounds
- Concomitant contra-labeled CYP/transporter therapies during active Tecfidera (Dimethyl Fumarate) administration
Logged Side-Effect Incidence (18 Reports)
Tecfidera (Dimethyl Fumarate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tecfidera (Dimethyl Fumarate))
Human clinical trial evidence for Tecfidera (Dimethyl Fumarate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Tecfidera (Dimethyl Fumarate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9402/unit (~$28.21/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $9.05 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $10.41 / mo | View logs ↓ |
Tecfidera (Dimethyl Fumarate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tecfidera (Dimethyl Fumarate) RxNorm Concept ID | 1373483-B64406006 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9402 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.05 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 91.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tecfidera (Dimethyl Fumarate) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Tecfidera (Dimethyl Fumarate) (multiple sclerosis agent) monograph synthesizing RxNorm 1373483-B64406006, openFDA FAERS signals, and $9.05–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tecfidera (Dimethyl Fumarate) community threads and patient logs by age, biological sex, dosage, and treatment duration.